13F Pro

SEC Form 4 reporting owner

Bienaime Jean Jacques

Bienaime Jean Jacques has filed 26 Form 4 transactions reported between March 9, 2026 and August 17, 2026, as a reporting owner of Keros Therapeutics, Inc., a reporting owner of Ascendis Pharma A/S, a reporting owner of Immunome Inc. and Director of INCYTE CORP.

Name as filed: BIENAIME JEAN JACQUES

Open-market buys, 24 mo
$1.0M
17 lines
Open-market sales, 24 mo
$204K
2 lines
Companies
4
with Form 4 filings
Latest transaction
Aug 17, 2026
transaction date

Roles and reported holdings

  • KROSKeros Therapeutics, Inc.
    Mar 9, 2026 – Aug 17, 2026

    Reporting owner

    Held directly19,592 sh as of Aug 17, 2026 · Form 4

    24 months: $76K bought

  • ASNDAscendis Pharma A/S
    May 26, 2026 – Aug 14, 2026

    Reporting owner

    Held directly2,900 sh as of Aug 14, 2026 · Form 4

    24 months: $607K bought

  • IMNMImmunome Inc.
    Mar 10, 2026 – Jun 10, 2026

    Reporting owner

    Held directly43,415 sh as of Jun 5, 2026 · Form 4

    24 months: $351K bought · $204K sold

  • INCYINCYTE CORP
    May 26, 2026 – Jun 8, 2026

    Director

    Held directly22,782 sh as of May 26, 2026 · Form 4

Transaction history

All 26 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

DateCompanyTypeSharesValueFiling
Aug 17, 2026KROSOpen-market purchaseCode P · direct1,000$10K@ $10.27Form 4
Aug 14, 2026ASNDOpen-market purchaseCode P · direct900$222K@ $246.91Form 4
Aug 14, 2026ASNDOpen-market purchaseCode P · direct1,100$270K@ $245.85Form 4
Jul 15, 2026KROSOpen-market purchaseCode P · direct1,000$11K@ $10.61Form 4
Jun 15, 2026KROSOpen-market purchaseCode P · direct1,000$10K@ $10.19Form 4
Jun 10, 2026IMNMGrant or awardCode A · direct9,897—Form 4
Jun 8, 2026INCYDirectorGrant or awardCode A · direct6,111—Form 4
Jun 8, 2026INCYDirectorGrant or awardCode A · direct1,642—Form 4
Jun 5, 2026IMNMOpen-market purchaseCode P · direct1,000$19K@ $19.27Form 4
Jun 5, 2026IMNMOpen-market purchaseCode P · direct3,500$68K@ $19.46Form 4
Jun 5, 2026IMNMOpen-market purchaseCode P · direct6,000$117K@ $19.48Form 4
Jun 5, 2026IMNMOpen-market saleCode S · direct10,000$194K@ $19.41Form 4
Jun 5, 2026IMNMOpen-market saleCode S · direct500$10K@ $19.44Form 4
Jun 3, 2026KROSGrant or awardCode A · direct7,433—Form 4
Jun 3, 2026KROSGrant or awardCode A · direct7,142—Form 4
May 29, 2026ASNDOpen-market purchaseCode P · direct100$22K@ $223.50Form 4
May 29, 2026ASNDOpen-market purchaseCode P · direct200$45K@ $223.76Form 4
May 26, 2026INCYDirectorShares withheld for tax or exercise priceCode F · direct13,059$1.3M@ $97.10Form 4
May 26, 2026INCYDirectorOption exerciseCode M · direct15,000$1.3M@ $84.53Form 4
May 26, 2026ASNDOpen-market purchaseCode P · direct200$47K@ $236.24Form 4
May 15, 2026IMNMOpen-market purchaseCode P · direct5,000$104K@ $20.70Form 4
May 15, 2026KROSOpen-market purchaseCode P · direct1,000$11K@ $10.58Form 4
Apr 15, 2026KROSOpen-market purchaseCode P · direct1,000$12K@ $11.70Form 4
Mar 11, 2026IMNMOpen-market purchaseCode P · direct1,000$22K@ $21.55Form 4
Mar 10, 2026IMNMOpen-market purchaseCode P · direct1,000$22K@ $22.12Form 4
Mar 9, 2026KROSOpen-market purchaseCode P · direct2,000$22K@ $11.21Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares owned after the latest purchase, sale, gift or tax-withholding line, shown separately for direct and indirect ownership; an indirect figure is one holding line, not a total across every trust or entity.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.